| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| R&D Expense | $14.6M | -7.3% | +22.8% |
| SG&A Expense | $4.7M | -19.0% | +8.1% |
| Operating Income | -$19.3M | +10.5% | -18.9% |
| Net Income | -$17.0M | +10.9% | -30.4% |
| EPS (Basic) | -$0.30 | +11.8% | -30.4% |
| EPS (Diluted) | -$0.30 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $15.1M | -23.4% | -50.3% |
| Short-term Investments | $190.9M | -2.9% | -14.7% |
| Current Assets | $209.0M | -4.9% | -18.7% |
| Total Assets | $211.8M | -5.0% | -19.1% |
| Current Liabilities | $11.2M | +27.7% | +50.3% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$42.4M | — | — |
| Capital Expenditures | $159K | — | — |
| Investing Cash Flow | $34.5M | — | — |
| Financing Cash Flow | $421K | — | — |
| Free Cash Flow | -$42.6M | — | — |
| -30.4% |
| $12.1M |
| +22.3% |
| +31.3% |
| Stockholders' Equity | $199.7M | -6.3% | -20.9% |